1月12日 - ** 制药商Soleno Therapeutics SLNO.O股价盘前上涨4.1%，至44.75美元
** 公司初步公布，自第二季度上市以来，2025年罕见病药物Vykat XR在美国的销售净收入在1.89亿美元至1.91亿美元之间。
** 高于分析师预计的 1.4296 亿美元--数据由 LSEG 编制
** 第四季度初步净营收预计在9000万美元至9200万美元之间，而预期为8167万美元。
** 截至上次收盘，股价在过去12个月中下跌了0.14%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.